Norges Bank Acquires Shares of 3,414,165 Royalty Pharma PLC $RPRX

Posted by Francis Steltz on Jun 5th, 2026

Norges Bank bought a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 3,414,165 shares of the biopharmaceutical company’s stock, valued at approximately $131,923,000.

A number of other hedge funds and other institutional investors have also modified their holdings of RPRX. Hillsdale Investment Management Inc. boosted its holdings in Royalty Pharma by 5,266.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 24,150 shares of the biopharmaceutical company’s stock valued at $933,000 after purchasing an additional 23,700 shares during the last quarter. Fideuram Asset Management Ireland dac purchased a new stake in Royalty Pharma during the 4th quarter worth approximately $413,000. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund purchased a new stake in Royalty Pharma during the 4th quarter worth approximately $9,063,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Royalty Pharma by 55.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 16,678 shares of the biopharmaceutical company’s stock valued at $644,000 after purchasing an additional 5,958 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Royalty Pharma by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 7,719,843 shares of the biopharmaceutical company’s stock valued at $297,465,000 after buying an additional 102,430 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Citigroup boosted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. UBS Group lifted their price target on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $53.71.

Check Out Our Latest Stock Analysis on Royalty Pharma

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $55.02 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. Royalty Pharma PLC has a 12 month low of $33.37 and a 12 month high of $56.07. The company has a fifty day moving average price of $50.63 and a two-hundred day moving average price of $44.93. The company has a market cap of $31.68 billion, a PE ratio of 37.43, a P/E/G ratio of 1.51 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million for the quarter, compared to the consensus estimate of $881.69 million. Research analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the completion of the transaction, the executive vice president directly owned 31,881 shares in the company, valued at $1,691,605.86. The trade was a 30.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the transaction, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 199,185 shares of company stock valued at $10,082,926 over the last quarter. Insiders own 18.84% of the company’s stock.

About Royalty Pharma

(Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.